Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-82 and Docetaxel in Advanced Solid Malignancies
NCT02146222Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vorolanib in solid tumor (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of toxicity graded according to NCI CTCAE version 4.0 up to 2 years, Changes in the FLT PET/CT vascular parameters for VEGF/PDGF dual kinase inhibitor X-82 and 1 more. Started Sep 2014; status: completed.
02
Drugs
vorolanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02146222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146222.